Michael Davidson urges earlier LDL treatment
- Michael Davidson says lifetime LDL exposure matters more than 10-year risk scores.
- Obicetrapib cut LDL up to 45% in Phase 3 trials.
- Prevail must show whether CETP inhibition prevents cardiovascular disease.
High LDL may be doing its damage decades before doctors usually intervene. On September 14, 2026, cardiologist Michael Davidson and Peter Attia argued that cholesterol treatment should begin early enough to prevent plaque, rather than wait for short-term risk calculators to identify patients already on the path to disease.
Davidson’s framework treats LDL exposure as cumulative. His eight-gram example estimates that maintaining 200 mg/dL over 40 years exposes artery walls to eight grams of circulating cholesterol. Keeping LDL below 80 mg/dL throughout life, he argues, could prevent vascular disease entirely. The claim pushes prevention toward lifetime exposure rather than the 10-year horizon used in current primary-prevention guidelines.
Attia compared LDL with smoking: Physicians do not ask smokers to wait until their near-term cancer probability rises before recommending cessation. The same logic applies to LDL, according to the discussion. A causal driver deserves early treatment, even when a 30-year-old’s risk score looks low.
"Treating causal drivers early beats clearing clogged arteries later."
- Peter Attia and Michael Davidson, The Peter Attia Drive
The drug update focused on obicetrapib, a CETP inhibitor designed to revive a class abandoned after earlier failures. Pfizer’s torcetrapib raised blood pressure and mortality through an off-target aldosterone effect. Later candidates from Roche and Lilly either lacked potency or were abandoned before proving their value, which Davidson says reflects toxic chemistry rather than a failed biological target.
New Amsterdam Pharma, Davidson’s company, acquired obicetrapib and tested a potent 10 mg dose alongside maximal statin therapy. Phase 3 results from the Broadway and Brooklyn trials showed LDL reductions of 35% to 45%, plus a 50% drop in Lp(a). Those results make obicetrapib a potentially useful tool for patients who need more aggressive lipid reduction than statins alone provide.
"Obicetrapib revives CETP inhibition by lowering LDL up to 45 percent without historic off-target toxicity."
- Michael Davidson, The Peter Attia Drive
The cardiovascular case remains ahead of the Alzheimer’s case. The discussion presents early LDL reduction as a possible way to protect both blood vessels and cognitive pathways, including for people with APOE4 risk, but the pending Prevail outcome trial will determine whether CETP inhibition reduces cardiovascular events in practice. Until then, the strongest evidence supports a sharper prevention strategy: reduce lifelong atherogenic exposure before plaque becomes the problem.